Marksans Pharma Ltd Q3 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/d90upmtyyns7pvn3qt5hx050.pdf

Key Takeaways


Teva Facility Ramp-Up

Mark Saldanha: "you have to get your team ready, you have to have your headcount, you have to have highly qualified people. You have to invest, you have to do the training. And so, you have a gestation of 6 months out there before you actually see optimization or operating leverage happening once they come on board."

Margin Dynamics


Revenue Growth & Geographic Mix

Mark Saldanha: "we no longer talk of INR 3,000 crores. We are already working towards the INR 4,000 crores mark, the business model and the strategy."

Tariffs & Geopolitical Risk

Mark Saldanha: "if it is uniformly, if there is no advantage per se... the cost will go up and that cost will have to be passed down."

Capital Allocation & M&A

Mark Saldanha: "Our history will say that we've never gone into some big-ticket deals. We are not averse to it, but we try to avoid any risk or you could say we do a risk mitigation to see that there is no devaluation on what we acquire."

Guidance & Commitments

CommitmentSpecificsTimeline
Freight cost drag to endFreight cost impact visible in Q4; no longer a drag on EBITDAFrom Q4 FY25 onward
Employee cost drag to normalizeEmployee cost from Teva facility becomes no drag on EBITDA as revenue growsNext 1–2 quarters
Teva next revenue milestoneAchieve INR 50 crores monthly run rate, then target INR 80 croresNo date; gated on hitting INR 50 crores first
Revenue targetINR 3,000 crores maintained; internally working toward INR 4,000 croresINR 3,000 crores targeted; INR 4,000 crores is the next milestone
U.K. revenue ambitionDouble U.K. revenueNo timeline; dependent on product approvals and pipeline
Teva revenue potentialINR 800+ crores from the acquired facilityNo date; long-term target

Key Metrics

MetricQ3 FY25
Operating revenue₹682 cr, +16.3% YoY
U.S. & North America revenue₹353 cr, +37.1% YoY
U.K. & EU formulation revenue₹258 cr, +2.6% YoY
Australia & New Zealand revenue₹47.2 cr, -2.8% YoY
Gross margin56.2%, expanded 279 bps YoY from 53.5%
EBITDA₹138.8 cr, +4.3% YoY
EBITDA margin20.4%, contracted 234 bps YoY
Profit after tax₹105.1 cr, +26.6% YoY, all-time high quarterly PAT
EPS₹2.3
R&D spend₹11.8 cr, 1.7% of consolidated revenue
Cash balance₹669 cr, debt-free as of 31 Dec 2024
Teva facility monthly run rate~₹30 cr, annualized ~₹360 cr; next milestone ₹50 cr then ₹80 cr
Teva facility capacity utilization~20%
Rest of plants capacity utilization~70%, maximum possible ~85%
Freight costs~₹40 cr for the quarter